chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pruritus, Vaccination site rash, Vaccination site swelling
Clinical narrative: the area on my arm where I received the injection turned red; the area on my arm where I received the injection turned red, became inflamed; the area on my arm where I received the injection turned red, became inflamed, and began to itch; rash of tiny bumps around the injection site; rash of tiny bumps around the injection site and it has continued to itch now for two days; site of my injection has been very hard; site of my injection has been very hard and sore; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 25Mar2021 at 15:30 (at the age of 42-years-old), as a single dose for COVID-19 immunisation. Medical history included inappropriate sinus tachycardia, occipital neuralgia and fruit allergy to bananas. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications included daily multivitamin minerals nos; vitamins nos (CENTRUM) from an unknown date. The patient previously took codeine (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced allergy. On 01Apr2021, the patient underwent COVID-19 PCR test (test type: Nasal swab) and tested negative. The patient reported that the site of injection had been very hard and sore since the first dose of Pfizer COVID-19 vaccination on 25Mar2021. One week later on 02Apr2021 at 14:00, the area on arm where the patient received the injection turned red, became inflamed, and began to itch. She then developed what seems to be a rash of tiny bumps around the injection site and it has continued to itch now for two days. The patient do not have any other symptoms so far. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events site of injection very hard and sore, injection site area that turned red, became inflamed and began to itch, rash of tiny bumps around the injection site that has continued to itch were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Hypoaesthesia, Hypoaesthesia oral, Lip pain, Pain in extremity
Clinical narrative: upper lip tingling; left side of face from forehead to chin, including eye, tingling/ left and right cheeks tingling; swollen vaccine site; unable to lift arm; Lower lip numb and Lip numbness on both lower and upper lips/ upper lip moderately numb; left side of face from forehead to chin, including eye, numb/ chin numb; burning; sharp pain in lower lip; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204 COA) via an unspecified route of administration in the right arm on 13Mar2021 at 10:00 (at the age of 57-year-old) as a single dose for COVID-19 immunisation. Medical history included 2007 lyme's disease, but no symptoms since 2007. The patient had known allergy to codeine. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) started on an unknown date for unspecified indication, loratadine (CLARITIN) started on an unknown date for unspecified indication and multivitamin (MANUFACTURER UNKNOWN) started on an unknown date for unspecified indication. Prior to the vaccination, the patient was not tested positive for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 13Mar2021, hours after vaccination, the patient experienced burning and sharp pain in lower lip.  On 14Mar2021, the patient experienced swollen vaccine site, unable to lift arm, lower lip and chin completely numb. On 15Mar2021, the patient experienced left side of face from forehead to chin, including eye, tingling and numb, lip numbness on both lower and upper lips. On 30Mar2021, the patient experienced left and right cheeks, upper lip tingling and moderately numb and reduction in numbness to just lower lip and chin, from 22- 29 March, reduced to lower lip numbness only. No therapeutic measures were taken as a result of the reported events. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events burning, sharp pain in lower lip, swollen vaccine site, unable to lift arm, chin completely numb left side of face from forehead to chin, including eye, tingling and numb, lip numbness on upper lips, moderately numb, left and right cheeks, upper lip tingling was recovering  and lower lip numb was not recovered at the time of this report.     No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia, Paraesthesia oral, Vaccination site swelling
Clinical narrative: upper lip tingling; left side of face from forehead to chin, including eye, tingling/ left and right cheeks tingling; swollen vaccine site; unable to lift arm; Lower lip numb and Lip numbness on both lower and upper lips/ upper lip moderately numb; left side of face from forehead to chin, including eye, numb/ chin numb; burning; sharp pain in lower lip; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204 COA) via an unspecified route of administration in the right arm on 13Mar2021 at 10:00 (at the age of 57-year-old) as a single dose for COVID-19 immunisation. Medical history included 2007 lyme's disease, but no symptoms since 2007. The patient had known allergy to codeine. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) started on an unknown date for unspecified indication, loratadine (CLARITIN) started on an unknown date for unspecified indication and multivitamin (MANUFACTURER UNKNOWN) started on an unknown date for unspecified indication. Prior to the vaccination, the patient was not tested positive for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 13Mar2021, hours after vaccination, the patient experienced burning and sharp pain in lower lip.  On 14Mar2021, the patient experienced swollen vaccine site, unable to lift arm, lower lip and chin completely numb. On 15Mar2021, the patient experienced left side of face from forehead to chin, including eye, tingling and numb, lip numbness on both lower and upper lips. On 30Mar2021, the patient experienced left and right cheeks, upper lip tingling and moderately numb and reduction in numbness to just lower lip and chin, from 22- 29 March, reduced to lower lip numbness only. No therapeutic measures were taken as a result of the reported events. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events burning, sharp pain in lower lip, swollen vaccine site, unable to lift arm, chin completely numb left side of face from forehead to chin, including eye, tingling and numb, lip numbness on upper lips, moderately numb, left and right cheeks, upper lip tingling was recovering  and lower lip numb was not recovered at the time of this report.     No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Hot flush, Nausea
Clinical narrative: Splitting headache; Extreme fatigue; Hot flashing; Felt nausea; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: PAA16596S/06/2022), via an unspecified route of administration in the left arm on 15Mar2021 at 11:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included Meniere's disease. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN), cetirizine hydrochloride (ZYRTEC), multivitamin (MANUFACTURER UNKNOWN), ubidecarenone (COQ10) and vitamin D not otherwise specified (NOS) (MANUFACTURER UNKNOWN) all since an unknown date for an unknown indication. The patient had no allergies to medications, food, or other products. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 15Mar2021 at 11:05, within 5 minutes of vaccination, the patient felt nausea and had nausea all day for 48 hours. Four hours after the shot, at 15:00, extreme fatigue had kicked in and experienced hot flashing. On 16Mar2021, the morning the patient woke up with a splitting headache that lasted for 24 hours. On 17Mar2021, the patient felt great and free of symptoms. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events felt nausea, extreme fatigue, hot flashing, and splitting headache were recovered on 17Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Rash on arms and torso; This is a spontaneous report received from a contactable healthcare professional (patient) via regulatory authority.   A 50-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613), via an unspecified route of administration in the left arm on 31Mar2021 at 10:00 (at the age of 50-year-old) as a single dose for COVID-19 immunization. Medical history included covid-19, thyroid goiter, hypothyroidism, Hashimoto's disease, food allergy to honey all from unknown dates. Prior to the vaccination, the patient was diagnosed with COVID-19 on an unknown date. Concomitant medications included levothyroxine sodium (SYNTHROID), and  unspecified vitamins (MANUFACTURER UNKNOWN), both taken from unknown dates for unknown indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunization. The patient did not receive any other vaccines within four weeks prior to the vaccination. Since the vaccination, the patient has not been tested for COVID-19. On 03Apr2021 at 08:00, the patient experienced rash on arms and torso. The event resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether the patient received any treatment for the event. The clinical outcome of rash on arms and torso was recovering at the time of the report.  No follow-up attempts are needed. No further information is expected
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: Hive-like rash; This is a spontaneous report from a contactable consumer, the patient. A 43-years-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the arm left on 30Mar2021 at 14:30 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included finasteride (MANAFACTURER UNKNOWN) from an unknown date for an unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the arm left on 09Mar2021 at 11:45 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had no known allergies. On 02Apr2021 the patient experienced hive-like rash that started on his both biceps and both upper thighs and then spread to underneath both arm pits and lower legs. The patient did not receive any treatment for the event. The clinical outcome of the event urticarial rash was unknown.  No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Body temperature, Chills, Hyperhidrosis
Clinical narrative: Lost the 30% of the smell; Loss the 30% of the taste; Fever; Chills; Sweats; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the right arm on 22Mar2021 at 15:45 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history included COVID-19. Concomitant medications included amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL) 20 mg from an unknown date for unknown indication. The patient previously received Morphine on unknown date for an unspecified indication and experienced drug allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Mar2021 at 21:00, approximately six hours after receiving the first vaccine, the patient experienced fever of 102, chills, sweats and nausea. On 23Mar2021, the patient had lost the 30% of the smell and taste that had regained over the last 6 months since having the COVID in Oct/Nov, all the smell and taste had gone again. Now two weeks later and still could not smell or taste. The event resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the reported events. On 03Apr2021, the patient underwent nasal swab test for SARS-CoV-2 (PCR) and the result was pending. The clinical outcomes of the events fever, chills, sweats, nausea, lost the 30% of the smell and taste were not recovered at the time of reporting.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Nausea, Pyrexia, SARS-CoV-2 test
Clinical narrative: Lost the 30% of the smell; Loss the 30% of the taste; Fever; Chills; Sweats; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the right arm on 22Mar2021 at 15:45 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history included COVID-19. Concomitant medications included amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL) 20 mg from an unknown date for unknown indication. The patient previously received Morphine on unknown date for an unspecified indication and experienced drug allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Mar2021 at 21:00, approximately six hours after receiving the first vaccine, the patient experienced fever of 102, chills, sweats and nausea. On 23Mar2021, the patient had lost the 30% of the smell and taste that had regained over the last 6 months since having the COVID in Oct/Nov, all the smell and taste had gone again. Now two weeks later and still could not smell or taste. The event resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the reported events. On 03Apr2021, the patient underwent nasal swab test for SARS-CoV-2 (PCR) and the result was pending. The clinical outcomes of the events fever, chills, sweats, nausea, lost the 30% of the smell and taste were not recovered at the time of reporting.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling, Skin discolouration, Skin warm
Clinical narrative: Left arm swelling; Left arm swelling/ hot/dark pink to the elbow.; Left arm swelling/ hot/dark pink to the elbow.; This is a spontaneous report from a contactable consumer, the patient. A 70-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8727) via unspecified route of administration in left arm on 28Mar2021, at 13:00 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient did not have any allergies to medications, food, or other products. Concomitant medications included pravastatin (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was diagnosed with COVID-19 on unspecified date. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 31Mar2021, the patient experienced left arm swelling, hot and dark pink to the elbow. The events resulted in a visit to the doctors or other healthcare professional office/clinic visit. The patient was advised by the nurse to take BENADRYL (patient took BENADRYL and swelling sent down in 3 days) and warm compression as treatment for the events. The clinical outcome of events left arm swelling, hot and dark pink to the elbow was resolved on 03April2021.   No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Contusion, Peripheral swelling
Clinical narrative: Severely bruised arm; Purple and blue size of soft ball have pictures; This is a spontaneous report from contactable consumer, the patient. A 48-years-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown); via unspecified route of administration in left arm on 02Apr2021 at 15:45 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food, or other products. The concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient was not diagnosed with COVID-19 prior to the vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 02Apr2021 at 16:00 the patient experienced arm was severely bruised, purple and blue size of soft ball had pictures. No therapeutic measures were taken as a result of reported events. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the events severely bruised arm and purple and blue size of soft ball was unknown.  No follow-up attempts are needed. information about lot number cannot be obtained.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: Light headed; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8732) via an unspecified route of administration in the left arm on 03Apr2021 at 08:30 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received amoxycillin and experienced allergy. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 03Apr2021, the patient experienced light headedness. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the event light headedness was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Oropharyngeal pain
Clinical narrative: Fairly severe sore throat 2 days after 2nd injection; This is a spontaneous report from a contactable consumer, the patient. A 72-year-old male patient received the second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA Vaccine; Lot number: EP7533), via an unspecified route of administration in the left arm on 01Apr2021 (at the age of 72-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient did not have any allergies to medications, food, or other products. The patient did not receive any medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA Vaccine; Lot number: EN6207), via an unspecified route of administration in the left arm on 11Mar2021 at 09:00 (at the age of 72-years-old), as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 03Apr2021 at 14:00, two days after the second vaccination, the patient experienced fairly severe sore throat. The patient did not receive any treatment for the event. The clinical outcome of the event fairly severe sore throat was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Diarrhoea, Fatigue, Headache, Musculoskeletal stiffness
Clinical narrative: after the vaccine, began to be nauseous,; rumblings in my stomach; diarrhea; severe tiredness; slight headache; slight pain or stiffness on left arm; slight pain or stiffness on  left arm; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 02Apr2021 at 09:30 hours (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included shellfish allergy, metal allergy and the patient was allergic to sulfur and sulfate. The patient did not take any concomitant medication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 09:30 hours, after the vaccine, the patient began to be nauseous and had rumblings in the stomach, diarrhea, severe tiredness, slight headache and slight pain or stiffness on the left arm from the shot. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events nauseous, rumblings in the stomach, diarrhea, severe tiredness, slight headache and slight pain or stiffness on the left arm were resolving at the time of report.  No follow-up attempts are possible. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain in extremity
Clinical narrative: after the vaccine, began to be nauseous,; rumblings in my stomach; diarrhea; severe tiredness; slight headache; slight pain or stiffness on left arm; slight pain or stiffness on  left arm; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 02Apr2021 at 09:30 hours (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included shellfish allergy, metal allergy and the patient was allergic to sulfur and sulfate. The patient did not take any concomitant medication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 09:30 hours, after the vaccine, the patient began to be nauseous and had rumblings in the stomach, diarrhea, severe tiredness, slight headache and slight pain or stiffness on the left arm from the shot. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events nauseous, rumblings in the stomach, diarrhea, severe tiredness, slight headache and slight pain or stiffness on the left arm were resolving at the time of report.  No follow-up attempts are possible. No further information is expected.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Headache, Myalgia, Pyrexia
Clinical narrative: Weekness; headaches; fevers; muscle achea; This is a spontaneous report from a contactable consumer, the patient. A 74-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 28Feb2021 at 10:30(at the age of 74-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as no. Concomitant medication was not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on an unknown date as a single dose for COVID-19 immunisation. The patient had no known allergies to medications, food, or other products. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 08Mar2021, the patient experienced weakness, headaches, fevers and muscle ache. The patient did not receive any treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the events weakness, headaches, fevers and muscle ache were not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Vaccination site pain
Clinical narrative: High fatigue; Injection site pain; This is a spontaneous report from a non-contactable consumer, the patient. A 26-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734), via an unspecified route of administration in the left arm on 30Mar2021 at 15:00 (at the age of 26-years-old), as a single dose for COVID-19 immunisation. Medical history included asthma and hazelnuts allergy. Concomitant medications included salbutamol (ALBUTEROL INHALER) and PORTIA birth control pill, both for an unknown indication and from unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route on an unknown date, as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021 at 04:45, the patient experienced high fatigue and injection site pain for 72 hours The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of reported events. The clinical outcome of the event high fatigue was recovered on an unknown date in 2021; while that of the event injection site pain for 72 hours was recovered on an unknown date in Apr2021.   No follow-up attempts are possible. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Nausea, Tremor, Wheezing
Clinical narrative: experienced mild wheezing.; experienced shaking hands and legs.; legs went weak; felt very nauseas/ nausea was more intense; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0105) via an unspecified route of administration in the right arm on 01Apr2021 at 14:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, COVID-19. The patient had history of known allergies to molds, pollen, dust mites, drugs allergy: codeine (MANUFACTURER UNKNOWN) and (DURICEF). Concomitant medications included fluticasone furoate (ARNUITY ELLIPTA) of 100mcg and loratadine (MANUFACTURER UNKNOWN) of 10mg tablet, all from unknown date for unknown indication and also previously second dose of varicella zoster vaccine rgE (CHO) (SHINGRIX) (Lot Number: 58160-0823-11 on 12Mar2021 for an unknown indication. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 01Apr2021 at 14:00, within five minutes of receiving the vaccine, the patient felt very nauseas, about 20 minutes after vaccine the legs went weak and nausea was more intense. Healthcare workers made the patient sit with feet propped up. About 30 minutes after vaccine the patient experienced shaking of hands and legs, about one hour after vaccine experienced mild wheezing. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures included treatment with inhaler, consumption of snack and water. The clinical outcomes for nausea, shaking of hands and legs, mild wheezing and weakness of legs were recovering.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster, SARS-CoV-2 test
Clinical narrative: Shingles on right side of lower torso; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the right arm on an unknown date in Mar2021 at 13:30 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history of the patient was not reported. The patient did not have allergies to medications, food, or other products. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Mar2021,  04Mar2021, 14Mar2021, 22Mar2021 the patient underwent nasal swab test for COVID-19 and the result for all the test was negative. On 05Mar2021 the patient experienced shingles on right side of lower torso. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported adverse event. The clinical outcome of the event shingles on right side of lower torso was resolved on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Rash, Swelling
Clinical narrative: Fever; body aches; rash on chest and stomach; rash on chest and stomach and swollen where rash is; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 31Mar2021 (at the age of 60-years-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any concomitant medications. Allergies to medications, food, or other products was reported as Bo. The patient previously received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 03Mar2021 (at the age of 60-years-old), as a single dose for COVID-19 immunisation. On 01Apr2021 at 00:00, the patient experienced fever, body aches, rash on chest and stomach and swollen where rash was. The events resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events fever, body aches, rash on chest and stomach and swollen where rash was were not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Influenza like illness
Clinical narrative: Flu like symptoms; This is a spontaneous report from a contactable consumer. A 69-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 69-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date the patient experienced flu like symptoms, lasted for two days post vaccination . The event did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event flu like symptoms was resolved on an unknown date.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Flushing, Heart rate increased
Clinical narrative: Rapid heart rate; flushing in body; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA Vaccine; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 24Mar2021 at 12:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had unspecified allergies to food, medications or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 24Mar2021 at 12:15, the patient experienced rapid heart rate and flushing in body. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events rapid heart rate and flushing in body was recovered on an unknown date in 2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Dizziness, Fatigue, Headache
Clinical narrative: Chills; headache; joint pain; muscle pain; injection site sorness; dizziness; nausea; tierdness; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received second dose of  BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: Ew0150)via an unspecified route of administration administered in the right arm on 01Apr2021 at 11:00 (at the age of 67-year-old) as a single dose for COVID-19 immunisation. Medical history included hepatitis c, arthritis, thyroid(hypothyroidism), essential tremor and the patient was allergic to sulfonamide and penicillin. Concomitant medications included bupropion hydrochloride (BUPROPION), escitalopram oxalate (LEXAPRO), levothyroxine sodium (LEVOXYL), gabapentin (MANUFACTURER UNKNOWN) and topiramate (TOPAMAX), all taken from unknown dates and for unknown indications. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EN6199) via an unspecified route of administration, administered in the right arm on 11Mar2021 at 10:45(at the age of 67-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 01Apr2021 at 18:00, the patient experienced  chills, headache, dizziness, joint pain, muscle pain, injection site soreness(vaccination site pain), nausea and tiredness. The patient did not receive any treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event chills, headache, dizziness, joint pain, muscle pain, injection site soreness, nausea and tiredness was recovering at the time of this report.  No follow-up attempts are needed; No further information is expected.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Vaccination site pain
Clinical narrative: Chills; headache; joint pain; muscle pain; injection site sorness; dizziness; nausea; tierdness; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received second dose of  BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: Ew0150)via an unspecified route of administration administered in the right arm on 01Apr2021 at 11:00 (at the age of 67-year-old) as a single dose for COVID-19 immunisation. Medical history included hepatitis c, arthritis, thyroid(hypothyroidism), essential tremor and the patient was allergic to sulfonamide and penicillin. Concomitant medications included bupropion hydrochloride (BUPROPION), escitalopram oxalate (LEXAPRO), levothyroxine sodium (LEVOXYL), gabapentin (MANUFACTURER UNKNOWN) and topiramate (TOPAMAX), all taken from unknown dates and for unknown indications. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EN6199) via an unspecified route of administration, administered in the right arm on 11Mar2021 at 10:45(at the age of 67-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 01Apr2021 at 18:00, the patient experienced  chills, headache, dizziness, joint pain, muscle pain, injection site soreness(vaccination site pain), nausea and tiredness. The patient did not receive any treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event chills, headache, dizziness, joint pain, muscle pain, injection site soreness, nausea and tiredness was recovering at the time of this report.  No follow-up attempts are needed; No further information is expected.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Nausea, Vomiting
Clinical narrative: Dizziness; Nausea; Vomiting; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8737) via an unspecified route of administration in the right arm on 01Apr2021 at 16:30 (at the age of 51-year-old) as a single dose for COVID-19 immunisation. Medical history included allergies to penicillin and sulfa since childhood. The patient had no concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the right arm on 11Mar2021 at 12:00 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccine within four weeks prior to the vaccination. On 02Apr2021 at 02:00, (also reported as approximately 10 hours after vaccination) the patient awoke with dizziness and nausea. This had been ongoing and was increased to vomiting and had included fatigue. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events dizziness, nausea, vomiting, and fatigue were not recovered at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Paraesthesia
Clinical narrative: Tingling in earlobe; numbed jawline; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 26Mar2021 at 09:00 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history. Concomitant medications included paracetamol (TYLENOL) and meloxicam (MANUFACTURER UNKNOWN), both taken for unknown indications from unknown dates. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Mar2021 at 09:30, the patient experienced tingling in earlobe and then numbed jawline. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcomes of the events tingling in earlobe and then numbed jawline were recovered on an unknown date.   No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Chills, Fatigue, Headache
Clinical narrative: Tongue swelling; Headache; Nausea; Tired; Chills; Muscle weakness; Fever 100.5; Joint pain; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 15Mar2021 at 14:00 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid polyarthritis, inflammatory polyarthritis, graves disease and allergy to bee stings and contrast dye. Concomitant medications included methotrexate (MANUFACTURER UNKNOWN) dose of 20mg weekly and thiamazole (METHIMAZOLE) dose of 7.5 mg daily; both for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date, as a single dose for COVID-19 immunisation and codeine for unknown indication on unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On an unknown date in 2021 after second dose of vaccination, the patient experienced tongue swelling, headache, nausea, tired, chills, muscle weakness, fever 100.5 and joint pain. On an unknown date, the body temperature was reported as 100.5 (unit unspecified). The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events tongue swelling, headache, nausea, tired, chills, muscle weakness, fever and joint pain was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.